Market research
MNKD MannKind Corp
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 7.9688
- Dividend yield
- Not available
- Beta
- 1.1
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US56400P7069
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 7.9688
- Dividend yield
- Not available
- Beta
- 1.1
About
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MNKD discussion.
5 years, 4 months ago
MannKind Corporation is currently in a long term uptrend where the price is trading 40.9% above its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 14.3.
MannKind Corporation's total revenue rose by 15.3% to $18M since the same quarter in the previous year.
Its net income has dropped by 85.2% to $-26M since the same quarter in the previous year.
Finally, its free cash flow grew by 18.6% to $-4M since the same quarter in the previous year.
Based on the above factors, MannKind Corporation gets an overall score of 4/5.